Rifampicin and clarithromycin (extended release) versus rifampicin and streptomycin for limited Buruli ulcer lesions: a randomised, open-label, non-inferiority phase 3 trial
Open Access
- 12 March 2020
- journal article
- research article
- Published by Elsevier BV in The Lancet
- Vol. 395 (10232), 1259-1267
- https://doi.org/10.1016/s0140-6736(20)30047-7
Abstract
No abstract availableKeywords
Funding Information
- WHO Ethics Review Committee (RPC443)
- University Medical Centre Groningen Ethics Review Board (M11.097746)
This publication has 37 references indexed in Scilit:
- Targeting the Mycobacterium ulcerans cytochrome bc1:aa3 for the treatment of Buruli ulcerNature Communications, 2018
- Epidemiology of Buruli Ulcer Infections, Victoria, Australia, 2011–2016Emerging Infectious Diseases, 2018
- Antibiotic complications during the treatment of Mycobacterium ulcerans disease in Australian patientsInternal Medicine Journal, 2017
- Clinical outcomes of Ghanaian Buruli ulcer patients who defaulted from antimicrobial therapyTropical Medicine & International Health, 2016
- Long Term Streptomycin Toxicity in the Treatment of Buruli Ulcer: Follow-up of Participants in the BURULICO Drug TrialPLoS Neglected Tropical Diseases, 2014
- Clinical and Bacteriological Efficacy of Rifampin-Streptomycin Combination for Two Weeks followed by Rifampin and Clarithromycin for Six Weeks for Treatment of Mycobacterium ulcerans DiseaseAntimicrobial Agents and Chemotherapy, 2014
- CONSORT 2010 Statement: Updated Guidelines for Reporting Parallel Group Randomised TrialsPLoS Medicine, 2010
- Orally Administered Combined Regimens for Treatment of Mycobacterium ulcerans Infection in MiceAntimicrobial Agents and Chemotherapy, 2007
- Factors associated with functional limitations and subsequent employment or schooling in Buruli ulcer patientsTropical Medicine & International Health, 2005
- Beliefs and attitudes toward Buruli ulcer in Ghana.The American Journal of Tropical Medicine and Hygiene, 2002